Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 5/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL582331 | 1.00 | ALDH1A1 (0.57) | ALDH1A1LMNAF2TSHRTDP1 | |
| SCHEMBL1162598 | 1.00 | ALDH1A1 (0.57) | ALDH1A1LMNAF2TSHRTDP1 | |
| SCHEMBL670258 | 1.00 | ALDH1A1 (0.57) | ALDH1A1LMNAF2TSHRTDP1 | |
| Water SCHEMBL7306062 | 0.98 | ALDH1A1 (0.55) | ALDH1A1LMNAF2TSHRTDP1 | |
| SCHEMBL6665458 | 0.98 | ALDH1A1 (0.55) | ALDH1A1LMNAF2TSHRTDP1 | |
| Hydrochloric Acid SCHEMBL29837305 | 0.98 | ALDH1A1 (0.55) | ALDH1A1LMNAF2TSHRTDP1 | |
| Water SCHEMBL1660792 | 0.98 | ALDH1A1 (0.55) | ALDH1A1LMNAF2TSHRTDP1 | |
| Water SCHEMBL365995 | 0.98 | ALDH1A1 (0.55) | ALDH1A1LMNAF2TSHRTDP1 | |
| Hydroxyamine SCHEMBL28505434 | 0.96 | ALDH1A1 (0.53) | ALDH1A1LMNAF2TSHRTDP1 | |
| SCHEMBL6658466 | 0.96 | ALDH1A1 (0.53) | ALDH1A1LMNAF2TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3710437-B1 | ENANTIOMERIC SEPARATION OF RACEMIC NICOTINE BY ADDITION OF AN O,O'-DISUBSTITUTED TARTARIC ACID ENANTIOMER OF LOW OPTICAL PURITY | SIEGFRIED AG (CH) | 2022-12-14 | — | — | EP | claimed |
| US-11407730-B2 | Preparation of racemic nicotine by reaction of ethyl nicotinate with N-vinylpyrrolidone in the presence of an alcoholate base and subsequent process steps | SIEGFRIED AG (CH) | 2022-08-09 | — | — | US | claimed |
| CN-114763339-A | Process for the preparation of triazine derivatives | 江苏恒瑞医药股份有限公司 | 2022-07-19 | — | — | CN | claimed |
| US-11279685-B2 | Enantiomeric separation of racemic nicotine by addition of an O,O″-disubstituted tartaric acid enantiomer | SIEGFRIED AG (CH) | 2022-03-22 | — | — | US | claimed |
| EP-3728215-B1 | ONE-POT PROCESS FOR THE PREPARATION OF RACEMIC NICOTINE BY REACTION OF ETHYL NICOTINATE WITH N-VINYLPYRROLIDONE IN THE PRESENCE OF SODIUM ETHANOLATE OR POTASSIUM ETHANOLATE OR MIXTURES THEREOF | SIEGFRIED AG (CH) | 2021-10-13 | — | — | EP | claimed |
| US-11091458-B2 | — | — | 2021-08-17 | — | — | US | claimed |
| US-20200331884-A1 | PREPARATION OF RACEMIC NICOTINE BY REACTION OF ETHYL NICOTINATE WITH N-VINYLPYRROLIDONE IN THE PRESENCE OF AN ALCOHOLATE BASE AND SUBSEQUENT PROCESS STEPS | SIEGFRIED AG (CH) | 2020-10-22 | — | — | US | claimed |
| US-20200331883-A1 | ENANTIOMERIC SEPARATION OF RACEMIC NICOTINE BY ADDITION OF AN O,O'-DISUBSTITUTED TARTARIC ACID ENANTIOMER | SIEGFRIED AG (CH) | 2020-10-22 | — | — | US | claimed |
| US-20150126743-A1 | Process For The Preparation Of Pyrido [2,1-A] Isoquinoline Derivatives Comprising Optical Resolution Of An Enamine | HOFFMANN-LA ROCHE INC. | 2015-05-07 | — | — | US | claimed |
| US-20130338366-A1 | PROCESS FOR THE PREPARATION OF PYRIDO [2,1-A] ISOQUINOLINE DERIVATIVES COMPRISING OPTICAL RESOLUTION OF AN ENAMINE | HOFFMANN LA ROCHE (US) | 2013-12-19 | — | — | US | claimed |
| WO-2008031749-A1 | PROCESS FOR THE PREPARATION OF PYRIDO[2,1-A]ISOQUINOLINE DERIVATIVES COMPRISING OPTICAL RESOLUTION OF AN ENAMINE | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-20 | — | — | WO | claimed |
| US-7161008-B2 | Optically active β-aminoketones, optically active 1,3-amino alcohols and processes for preparing them | Sanofi - Aventis Deutschland GmbH (DE) | 2007-01-09 | — | — | US | claimed |
| CN-1211366-C | Methyl sulfonate trihydrate of 1-(4-hydroxy phenyl)-2-(4-hydroxy-4-phenyl piperid-1-yl)-1-propanol and its intermidiate preparing process | PFIZER PROD INC (US) | 2005-07-20 | — | — | CN | claimed |
| EP-1149831-B1 | Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol and intermediates useful therefor | PFIZER PROD INC (US) | 2004-09-01 | — | — | EP | claimed |
| US-20040030145-A1 | Optically active B-aminoketones, optically active 1,3-amino alcohols and processes for preparing them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-12 | — | — | US | claimed |
| US-6570018-B2 | Reducing the propanone of the compound with an alkali metal borohydride and cleaving the protecting group in the presence of methanesulfonic acid; n-methyl-d-aspartic acid receptor antagonist; longer shelf life | PFIZER INC | 2003-05-27 | — | — | US | claimed |
| US-20020016466-A1 | Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol and intermediates useful therefor | PFIZER INC. | 2002-02-07 | — | — | US | claimed |
| CN-1322716-A | Methyl sulfonate trihydrate of 1-(4-hydroxy phenyl)-2-(4-hydroxy-4-phenyl piperid-1-yl)-1-propanol and its intermidiate preparing process | PFIZER PROD INC (US) | 2001-11-21 | — | — | CN | claimed |
| EP-1149831-A1 | Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol and intermediates useful therefor | Pfizer Products Inc. (US) | 2001-10-31 | — | — | EP | claimed |
| EP-0029175-B1 | PROCESS FOR THE OBTENTION OF THE ENANTIOMERIC FORMS OF 4-CYANE-1-(N-METHYL-N-(2'-((3\",4\"-DIMETHOXYPHENYL))ETHYL-AMINO)-5-METHYL-4-(3',4',5'-TRIMETHOXYPHENYL) HEXANE AND ITS SALTS | BASF Aktiengesellschaft (DE) | 1982-12-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331883-A1 | ENANTIOMERIC SEPARATION OF RACEMIC NICOTINE BY ADDITION OF AN O,O'-DISUBSTITUTED TARTARIC ACID ENANTIOMER | CHRNB1, CHRNA1, CHRM1 | ALDH1A1 129/4885LMNA 4014/4885F2 3196/4885 |
| US-20040030145-A1 | Optically active B-aminoketones, optically active 1,3-amino alcohols and processes for preparing them | ORMDL3, OR10J3, BCAT2 | ALDH1A1 59/4885LMNA 2390/4885F2 805/4885 |
| US-20020016466-A1 | Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol and intermediates useful therefor | CYP4A11, CYP2S1, CYP4B1 | ALDH1A1 14/4885LMNA 4184/4885F2 1986/4885 |
| US-11279685-B2 | Enantiomeric separation of racemic nicotine by addition of an O,O″-disubstituted tartaric acid enantiomer | CHRNB1, CHRNA1, CHRM1 | ALDH1A1 129/4885LMNA 3991/4885F2 3214/4885 |
| US-20130338366-A1 | PROCESS FOR THE PREPARATION OF PYRIDO [2,1-A] ISOQUINOLINE DERIVATIVES COMPRISING OPTICAL RESOLUTION OF AN ENAMINE | PNPO, ENO1, CHRM1 | ALDH1A1 1362/4885LMNA 1512/4885F2 352/4885 |
| US-20200331884-A1 | PREPARATION OF RACEMIC NICOTINE BY REACTION OF ETHYL NICOTINATE WITH N-VINYLPYRROLIDONE IN THE PRESENCE OF AN ALCOHOLATE BASE AND SUBSEQUENT PROCESS STEPS | NNMT, NAPRT, NAMPT | ALDH1A1 584/4885LMNA 2920/4885F2 2837/4885 |
| US-11091458-B2 | — | NNMT, CHRNA5, NAPRT | ALDH1A1 550/4885LMNA 2721/4885F2 2875/4885 |
| US-20150126743-A1 | Process For The Preparation Of Pyrido [2,1-A] Isoquinoline Derivatives Comprising Optical Resolution Of An Enamine | PNPO, ENO1, CHRM1 | ALDH1A1 1362/4885LMNA 1512/4885F2 352/4885 |
| US-11407730-B2 | Preparation of racemic nicotine by reaction of ethyl nicotinate with N-vinylpyrrolidone in the presence of an alcoholate base and subsequent process steps | NNMT, NAPRT, NAMPT | ALDH1A1 584/4885LMNA 2920/4885F2 2837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.